MDCX ’s lead asset is Skinkject, a patented innovative product intended to address the most commonly occurring cancer, which is skin cancer, or Basal Cell Carcinoma (BCC). Skinject is a thumb-sized ...

MSPs get to benefit from every important IT trend that comes along, whether that's cybersecurity or data and AI,' said FFL's ...

Abacus Group and Medicus IT, two leading providers of IT managed services with deep subject matter expertise in the highly ...

FFL Partners ("FFL"), a private equity firm focused on growth investments in tech-enabled business services and healthcare companies, today announced the completion of the merger of FFL portfolio ...

Medicus Pharma offers high-risk, high-reward potential, with its novel SkinJect patch for basal cell carcinoma and Antev ...

Philadelphia, Pennsylvania--(Newsfile Corp. - July 8, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce submission of a comprehensive package to the United ...

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in. The post Is it too late to ...

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.

In April, Medicus Pharma Ltd. MDCX agreed to acquire all of Antev’s issued and outstanding shares on a share exchange. Antev is a clinical-stage biotech company developing Teverelix, ...

ASX 200 healthcare shares led the market last week, propelled by yet another share price surge for market darling Pro Medicus ...

Pro Medicus is in a strong financial position. As of June 2024, it had AUD 155 million in net cash, and we forecast the company to continue holding net cash over our explicit 10-year forecast period.